journal article·2023-10

A Novel Photosynthetic Biohybrid System for Microenvironment Regulation of Diabetes Retinopathy through Continuous Oxygen Supply and Nanozyme Cascade Reaction

Liyang Zhou, Kaiyue Lan, Xiaomin Huang, Yuyan Huang, Yingying Jin, Si Lu, Yishun Guo, Lili Su, Yaou Peng, Zhennv Deng, Jianhua Yang, Siyuan Qian, Wanqing Lou, Xiaoying Chu, Hanwen Guo, Bailiang Wang

Advanced Functional Materials· Volume 33· Issue 44
Publisher page

Abstract

Abstract According to International Diabetes Federation Diabetes Atlas statistics, diabetic retinopathy (DR) is the leading cause of vision loss in blinding diseases. The underlying cause of retinal vasculopathy progression in diabetic patients is hyperglycemia and hypoxia features in microvascular region. Hence, cyanobacteria are used as carriers to load both gold nanoparticles (Au NPs) with glucose oxidase‐like activity and iridium nanoparticles (Ir NPs) with catalase‐like activity, respectively (Cyano@Au@Ir). The Au NPs nanozyme first degrades glucose into hydrogen peroxide, which is further decomposed into H2O and O2 by the Ir NPs to complete the cascade hypoglycemic reaction. Based on the unique light transmittance of eyeball and the accumulation of light in the retinal area, the sustainable O2 production by Cyano greatly alleviates the hypoxia of microenvironment, leading to the decrease of angiogenic growth factor and hypoxia‐inducible factor expressions. Simultaneously, the highly expressed peroxide in the DR microenvironment can also be eliminated by Ir NPs for anti‐inflammatory property. Furthermore, it is demonstrated in DR animal model that Cyano@Au@Ir significantly reduces neovascular progression and vascular leakage. This novel treatment mode fundamentally degrades blood glucose, continuously supplies O2, and scavenges free radicals for comprehensive microenvironment regulation, providing inspirations for solving fundus complications of DR.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Advanced Nanomaterials in Catalysis · Nanoplatforms for cancer theranostics · Retinal Diseases and Treatments

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Ophthalmology Aier Eye Hospital of Wuhan University Wuhan 430000 China

National Engineering Research Center of Ophthalmology and Optometry Eye Hospital Wenzhou Medical University Wenzhou 325027 China

State Key Laboratory of Ophthalmology Optometry and Visual Science Eye Hospital Wenzhou Medical University Wenzhou 325027 China

NMPA Key Laboratory for Clinical Research and Evaluation of Medical Devices and Drug for Ophthalmic Diseases Eye Hospital Wenzhou Medical University Wenzhou 325027 China

Funding

Natural Science Foundation of Zhejiang Province

References (55)

Show source-provided references
1. 10.1016/j.diabres.2021.10911810.1016/j.diabres.2021.109118 ↗
2. 10.1016/j.diabres.2021.10911910.1016/j.diabres.2021.109119 ↗
3. 10.1002/(SICI)1520-7560(199907/08)15:4<261::AID-DMRR43>3.0.CO;2-Z10.1002/(SICI)1520-7560(199907/08)15:4<261::AID-DMRR43>3.0.CO;2-Z ↗
4. 10.1038/nm.405910.1038/nm.4059 ↗
5. 10.1136/bjophthalmol-2011-30064010.1136/bjophthalmol-2011-300640 ↗
6. 10.1007/s11892-015-0686-210.1007/s11892-015-0686-2 ↗
7. 10.1155/2007/9510310.1155/2007/95103 ↗
8. 10.1186/s12933-016-0397-210.1186/s12933-016-0397-2 ↗
9. 10.1016/j.jcjd.2020.10.00910.1016/j.jcjd.2020.10.009 ↗
10. 10.1021/acsnano.2c0544710.1021/acsnano.2c05447 ↗
11. 10.1002/smll.20190277610.1002/smll.201902776 ↗
12. 10.1007/s00417-010-1315-z10.1007/s00417-010-1315-z ↗
13. 10.1016/j.preteyeres.2020.10090610.1016/j.preteyeres.2020.100906 ↗
14. 10.1080/08820538.2017.135382010.1080/08820538.2017.1353820 ↗
15. 10.1007/s40820-020-00525-y10.1007/s40820-020-00525-y ↗
16. 10.1002/smll.20220340010.1002/smll.202203400 ↗
17. 10.1016/j.nantod.2021.10107610.1016/j.nantod.2021.101076 ↗
18. 10.1016/j.nantod.2023.10175510.1016/j.nantod.2023.101755 ↗
19. 10.1039/D0BM01118E10.1039/D0BM01118E ↗
20. 10.1002/adma.20180469310.1002/adma.201804693 ↗
21. 10.1039/D1DT03110D10.1039/D1DT03110D ↗
22. 10.1007/s40820-019-0305-x10.1007/s40820-019-0305-x ↗
23. 10.7150/thno.2759810.7150/thno.27598 ↗
24. 10.1126/sciadv.160307810.1126/sciadv.1603078 ↗
25. 10.1007/s12274-020-3094-010.1007/s12274-020-3094-0 ↗
26. 10.1002/adtp.20200010710.1002/adtp.202000107 ↗
27. 10.1126/scirobotics.aaq115510.1126/scirobotics.aaq1155 ↗
28. 10.1126/sciadv.aba599610.1126/sciadv.aba5996 ↗
29. 10.1007/s12274-020-3094-010.1007/s12274-020-3094-0 ↗
30. 10.1002/advs.20180173310.1002/advs.201801733 ↗
31. 10.1002/smll.20200081910.1002/smll.202000819 ↗
32. 10.1002/ange.20191282410.1002/ange.201912824 ↗
33. 10.1002/adfm.20220187510.1002/adfm.202201875 ↗
34. 10.1016/j.bioactmat.2021.10.03210.1016/j.bioactmat.2021.10.032 ↗
35. 10.2147/IJN.S25749910.2147/IJN.S257499 ↗
36. 10.1104/pp.100.2.78410.1104/pp.100.2.784 ↗
37. 10.1128/AEM.67.12.5351-5361.200110.1128/AEM.67.12.5351-5361.2001 ↗
38. 10.1016/j.biomaterials.2021.12070610.1016/j.biomaterials.2021.120706 ↗
39. 10.1021/ja409738410.1021/ja4097384 ↗
40. 10.1002/adma.20220969010.1002/adma.202209690 ↗
41. 10.1016/j.nantod.2021.10129710.1016/j.nantod.2021.101297 ↗
42. 10.1038/nrdp.2016.1210.1038/nrdp.2016.12 ↗
43. 10.1021/ja305154a10.1021/ja305154a ↗
44. 10.1016/j.bioactmat.2021.08.01210.1016/j.bioactmat.2021.08.012 ↗
45. 10.1021/acsnano.1c0068010.1021/acsnano.1c00680 ↗
46. 10.1167/iovs.61.13.2510.1167/iovs.61.13.25 ↗
47. 10.1016/j.drudis.2019.05.00510.1016/j.drudis.2019.05.005 ↗
48. 10.1038/s41551-021-00764-310.1038/s41551-021-00764-3 ↗
49. 10.1016/j.biomaterials.2012.01.03010.1016/j.biomaterials.2012.01.030 ↗
50. 10.1021/nn103146p10.1021/nn103146p ↗
51. 10.3389/fphar.2020.0046010.3389/fphar.2020.00460 ↗
52. 10.2337/db11-031510.2337/db11-0315 ↗
53. 10.1073/pnas.201723411710.1073/pnas.2017234117 ↗
54. 10.1002/jcb.2557510.1002/jcb.25575 ↗
55. 10.1002/adfm.20210561410.1002/adfm.202105614 ↗